PharmaMar is a company focused on oncology and committed to research and development which takes inspiration from the sea to discover molecules with antitumor activity. We are an integrated company that seeks innovative products to provide healthcare professionals with new tools to treat cancer.
Contact
Mooslackengasse 17, 1190 Wien
Tel +43 1 25301-62354
Website https://www.pharmamar.com/
Email pharmamar@pharmamar.com
Mario Huber, general manager of PharmaMar Austria, a multinational and an innovative oncology-based Spanish company, discusses the growth of the company in Austria and the reasons behind the success of…
A roundup of the latest news from Spanish pharma, including Almirall’s earnings forecast for 2023; stock price rise and layoffs at Grifols; PharmaMar’s first European approval for its lurbinectedin treatment…
A roundup of the latest news from Spanish pharma, including J&J’s COVID-19 vaccine trial, the latest developments at Spanish firm PharmaMar which hopes its Aplidin can be used as a…
PharmaMar, a Spanish firm, is beginning Phase II clinical trials for its anti-tumour drug Aplidin to treat coronavirus. The firm’s stocks have soared on the news. PharmaMar is joining…
Mario Huber, general manager of PharmaMar Austria, a multinational and an innovative oncology-based Spanish company, discusses the growth of the company in Austria and the reasons behind the success of…
Like a family recipe that has been refined and perfected over countless generations, Austria has developed a reputation as the quintessential clinical trials destination; a perfect combination of world-class academia,…
See our Cookie Privacy Policy Here
